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Abstract 
Aims: Resource allocation amongst competing health care interventions is informed by evidence of 
both clinical- and cost-effectiveness. Cost-utility analysis is increasingly used to assess cost 
effectiveness through the use of Quality Adjusted Life Years (QALYs). This requires health state 
values. Generic measures of health related quality of life (HRQL) are usually used to produce these 
values, but there are concerns about their relevance and sensitivity in epilepsy. This study develops a 
health state classification system for epilepsy from the NEWQOL battery, a validated questionnaire 
measuring QoL in epilepsy.  The classification system will be amenable to valuation for calculating 
QALYs.  
Methods: Factor and other psychometric analyses were undertaken to investigate the factor 
structure of the battery, and assess the validity and responsiveness of the items. These analyses 
were used alongside Rasch analysis to select the dimensions included in the classification system, 
and the items used to represent each domain. Analysis was carried out on a trial dataset of patients 
with epilepsy (n=1611). Rasch and factor analysis were performed on one half of the sample and 
validated on the remaining half. Dimensions and items were selected that performed well across all 
analyses. 
Results: The battery was found to demonstrate reliability and validity but responsiveness across time 
periods for many of the items was low.  A six dimension classification system was developed: worry 
about seizures, depression, memory, cognition, stigmatism and control, each with four response 
levels.  
Conclusions: It is feasible to develop a health state classification system from a battery of 
instruments using a combination of classical psychometric, factor and Rasch analysis.  This is the first 
condition-specific health state classification developed for epilepsy and the next stage will produce 
preference weights to enable the measure to be used in cost-utility analysis.   
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Introduction 
As with healthcare in general, resources available for epilepsy are limited and need to be allocated 
efficiently. The allocation process is typically informed by economic evaluations of competing health 
technologies.  Methods to evaluate the cost effectiveness of emerging interventions include the 
assessment of cost utility through the generation of Quality Adjusted Life Years (QALYs). QALYs 
provide a single measure of an individual’s preference for a particular health state by combining an 
assessment of both quantity and quality of life (Torrance, 1986).  In their guidelines for conducting 
economic evaluations, the National Institute for Health and Clinical Excellence (NICE) in England 
recommend the use of QALYs to measure the benefits of health interventions (National Institute for 
Health and Clinical Excellence, 2008). 
QALYs are commonly generated using generic preference-based measures (PBM) of health such as 
the EQ-5D (Brooks, 1996; Dolan, 1997), or the SF-6D (Brazier, 2002).  The EQ-5D is the measure for 
economic evaluations preferred by NICE and contains five dimensions (mobility, self care, usual 
activities, pain/discomfort, anxiety/depression), each with three health state levels.  This means that 
it is possible to generate a total of 243 (35) health states from the instrument.  To elicit preferences 
for each EQ-5D health state and to generate a preference-based single index score, a selection of the 
health states were valued using the standard preference elicitation technique Time Trade Off (TTO) 
developed by Torrance et al. (1972).  The EQ-5D index scores range from -0.594 to 1, and are 
anchored at 0 for dead and 1 for full health (where minus scores are states that have been valued as 
worse than dead).   
Epilepsy is a common neurological disorder that affects approximately 456,000 people of all ages in 
the United Kingdom (NHS, 2008).  The condition is characterised by repeated seizures and the 
majority of recommended treatments are pharmacological.  Research has focused on the positive 
and negative influences of experiencing epilepsy on health related quality of life (HRQL), and these 
include psychological comorbidities (Ettinger et al., 2004; Loring et al., 2004; Zeber et al., 2007), 
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stigma (Suurmeijer, 2001) and frequency or freedom from seizure (Birbeck et al., 2002; Jacoby et al., 
1992). Reviews of this area have been published by Jacoby et al. (2008; 2009).  However there is still 
more work required to define further the psychosocial and economic consequences of epilepsy.  
Generic PBMs are generally used in the economic evaluation of interventions for epilepsy.  However 
there is debate around their validity, and therefore the extent to which an accurate assessment of 
epilepsy specific cost utility can be made. For example, Stavem et al. (2001) found that some of the 
EQ-5D dimensions discriminated well by seizure status, but were less valid in patients who have used 
antiepileptic drugs and those with neurologic comorbidities.  Selai et al (2000) found that the EQ-5D 
was not capturing all of the HRQL issues of relevance to patients with chronic intractable epilepsy, 
and the measure did not display responsiveness within this group.  
Due to the uncertainty around using generic PBMs, there has been recent interest in developing 
condition-specific PBMs from non-preference-based condition-specific measures of Health Related 
Quality of Life (HRQL) (Brazier et al, 2008; Yang et al; 2008; Young et al, 2009). Standard condition-
specific HRQL measures do not generate single index utility scores and therefore cannot be used to 
calculate QALYs.  However they provide a strong basis for the first stage of the development of 
condition-specific PBMs which is the generation of a reduced health state classification system from 
the parent measure that is amenable to subsequent valuation.  In recent work, a combination of 
classical psychometric and Rasch analysis (Rasch, 1960) has been used to develop condition-specific 
health state classification systems for overactive bladder syndrome (Young et al., 2009), asthma 
(Young et al., 2010), flushing symptoms (Young et al. 2010) and dementia (Mulhern et al., 2010).  
Classical psychometric techniques and Rasch analysis are used to investigate the factor structure of 
the instrument and the analyses are combined with clinical input to subsequently select an item that 
represents each factor.  Combining these techniques is an accepted method of developing HRQL 
instruments (Tennant et al, 2004).   
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This technical report describes the first stage of the development of an epilepsy specific PBM.  This 
involves the application of psychometric and Rasch analysis to develop a condition-specific health 
state classification system from an existing measure of HRQL in epilepsy.  The parent instrument 
used is the NEWQOL (Abetz et al., 2000) which has been validated for use with patients with newly 
diagnosed epilepsy and has been used as a measure of HRQL in a large scale randomised controlled 
trial (RCT; Marson et al., 2005; 2007).  The reduced health state classification system will 
subsequently be valued by both patients and the general population using a standard preference 
elicitation technique. The general population weights will provide a tool to inform the economic 
evaluation of epilepsy interventions. 
 
Method 
Sample 
The sample used in this study consists of 1611 respondents with newly diagnosed epilepsy.  The data 
was collected as part of the SANAD study (Marson et al. 2005; 2007), an RCT of immediate and 
deferred antiepileptic drug treatment carried out in UK outpatient clinics.  The baseline data was 
used for this analysis.  Of the overall sample, 54% were male and the mean age was 39 (range 16 to 
86).  Furthermore, 70% reported that their general health was “good” or “better” and 40% had 
experienced 10 or more seizures. Classical psychometric analyses (including factor analysis) were 
carried out on the full sample.  The optimum number for Rasch analysis is 500 (Linacre, 1999), so 
therefore the sample used here was randomly split into two halves and the analysis was carried out 
on the first random half of the data (initial analysis) and validated on the second random half 
(validation analysis).   
 
Materials 
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The NEWQOL measure was developed by Abetz et al. (2000) to assess HRQL in recently diagnosed 
epilepsy, and a subset of the items are included in this study.  NEWQOL consists of a range of 
validated measures developed both for general use across a range of conditions and specifically for 
epilepsy.  The subset of NEWQOL measures and items (n=82) included in the initial analysis for this 
study assess mental health, cognition and neuropsychological problems, mastery/locus of control, 
stigma related to having epilepsy, the impact of epilepsy on a number of life areas, worry about 
seizures, social restrictions, and a full range of adverse events related to epilepsy. The measures 
included are the A-B Neuropsychological Assessment Schedule (ABNAS, Aldenkamp et al, 2002), 
Liverpool Adverse Events Profile (AEP, Baker et al., 1995), Hospital Anxiety and Depression Scale 
(HADS, Zigmond & Snaith, 1983), the mastery/locus of control scale (Pearlin & Schooler, 1974), 
stigma scale (Jacoby, 1994), the perceived impact of seizures scale (Jacoby et al., 1994), a social 
restriction item (Jacoby et al., 1992), and the seizure worry scale (Jacoby, 1994). Table 1 provides 
further details about each of the measures. 
 
Analysis  
The intention of the analysis was to derive a multidimensional patient reported health state 
classification system from the NEWQOL measure.  The number of items included in the classification 
system is reduced to one per dimension whilst retaining as many of the epilepsy-specific HRQL 
concepts included in the original NEWQOL as possible. A series of steps guides the analysis process 
(see figure 1), which involves applying the classical psychometric methods and Rasch analysis 
outlined below to produce the final classification system. Input from a range of experts including 
epilepsy clinicians and the developers of a selection of the measures included in the NEWQOL 
battery were also involved in the selection of the classification system.  This ensured that the item 
selected for each dimension was relevant to epilepsy and displayed good face validity.  Item text and 
the associated response options that are selected for each dimension of the classification system 
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form the basis of the health state levels used to generate epilepsy specific health states that are 
subsequently valued.  It is important to alter the text of the original item as little as possible so that 
responses can be clearly mapped onto the classification.  Psychometric and factor analysis was 
carried out using SPSS version 16 (SPSS, 2007) and Rasch analysis using Rasch Unidimensional 
Measurement Models 2020 (Rasch Unidimensional Measurement Models, 1997-2004).  
 
Stage 1: Establishing NEWQOL dimensionality: 
The dimensionality of the NEWQOL and the domains to be included in the classification system were 
established using exploratory factor analysis and input from epilepsy clinicians.  Factor analysis 
assesses the factor structure of instruments by examining the correlation between each item and a 
range of factor structures.  These were defined both by using the standard criterion of eigenvalues > 
1 and by forcing a range of solutions. Factor solutions with 4 to 12 factors were investigated.  Items 
were removed from factors if they did not load ≥ 0.4  on any factor, or cross loaded within 0.2 across 
more than one factor (Ferguson & Cox, 1993).  
 
Stage 2: Rasch analysis to eliminate items per dimension: 
Rasch analysis is part of the item response theory (IRT) group of analysis techniques.  Rasch converts 
responses to items into a continuous logit scale whereby the position of the individual is related to 
the severity of the underlying trait that the scale is measuring.  In the development of health 
instruments the underlying trait is the aspect of HRQL that the item assesses. Item responses are 
assumed to be a function of the location of both the person and the item on the logit scale.  Rasch 
analysis is applied to each of the dimensions. This is because the technique assumes 
unidimensionality so is therefore used to assess items that are measuring the same underlying 
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construct as suggested by the factor analysis.  The following criteria guide the selection of items for 
each domain. 
Item level ordering 
The ordering of the item response categories is investigated.  If items are disordered it demonstrates 
that responders cannot differentiate between item levels.  The response levels of disordered items 
are merged and the Rasch model is refitted.  If this occurs then the item is excluded from the 
selection process, although they are retained in the Rasch model.  
Differential item functioning 
Items are checked for Differential Item Functioning (DIF) which assesses whether responses to items 
differ dependent on participant characteristics.  There are two types of DIF, uniform and non 
uniform.  Uniform DIF occurs when responses between groups consistently differs across the logit 
scale (for example females consistently score more highly on a certain trait than males).  Non-
uniform DIF occurs when responses systematically differ at different severity levels.  In this study DIF 
by both gender and age group (split as age 16-35 (47% of the sample), 36-55 (34%) and 56 or older 
(19%)) has been investigated.  If any items display DIF they are split into component factors and the 
model is refitted.  Items split for DIF are no longer considered for inclusion in the  classification 
system. 
Goodness of fit 
Goodness of fit is investigated with the aim of removing items that do not fit the overall dimension 
level Rasch model and so are not consistent with the unidimensional scale.  The objective is to 
ensure that the items included in the final model, and therefore available for selection, all fit the 
Rasch model and provide overall goodness of fit.  This is done by studying item-trait interactions, 
and item and person fit residuals.   
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Item trait interactions: 
Item trait interactions assess the fit of items to the model for responders (dependent on the position 
of the respondent lie on the latent scale).  The overall difference between the observed and 
expected response is measured using the chi-squared (χ2) test statistic which is non-significant (i.e. > 
0.01) for a model providing good fit.  The lowest fitting items are removed sequentially until the 
remaining items fit the model and the overall fit statistic is non significant.  Items that are removed 
from the model will not be considered for the final classification system.   
Item/person fit residuals: 
Item fit residuals assess the amount of divergence between the expected and observed responses 
for each item included in the model. Person fit residuals assess the difference for individual 
respondents.  The mean fit residual should be approximately 0 and the standard deviation around 1, 
and residuals > 2.5 or < -2.5 are considered high and indicate a large divergence from what is 
expected for that item or individual.  Items and persons significantly outside this range are removed 
and the model is refitted.  
 
Stage 3: Psychometric and Rasch analysis to select one item per dimension 
After applying the tests included at stage 2, most dimensions have more than one item that could be 
included in the classification system.  Stage three involves selecting the most appropriate item from 
each dimension.  A selection of classical psychometric and Rasch statistics guides this process.  The 
psychometric tests carried out in this study included missing data, floor/ceiling effect and 
responsiveness analysis.  The main Rasch criteria used are the item spread at logit 0 (i.e. the spread 
of response at the average item difficulty) and the item range.  High spread and item range indicate 
that the item cover a large range of condition severity.  Good item range incorporates values above 
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and below 0 (i.e. more severe and less severe cases respectively). Item goodness of fit statistics and 
clinical input are also used to guide the selection process. 
Stage 4: Item level reduction 
Analysis of the performance of each item level is carried out to investigate whether the number of 
response levels included for each item can be reduced.  This is because it is essential to ensure that 
information relating to item levels is not redundant.  It is also possible that respondents will have 
difficulties distinguishing between response levels, and therefore the valuation of the health states 
will be more complex than if the item levels are collapsed.  The distribution of responses across each 
category is investigated, as is the ordering of the levels on the Rasch logit scale. 
 
Results: 
Stage 1: Establishing NEWQOL dimensionality: 
Factor analysis: 
The five factor solution explaining 53.3% of the variance in the model provided the best fit and 
included factors defined as cognition and memory, mental health, control, stigma and impact of 
epilepsy.  The items included in each factor are displayed in table 2. 
Selection of dimensions for the classification system: 
A number of alterations and additions were made to the initial factor structure to ensure that the 
classification system included as many facets of epilepsy related HRQL as possible.  It was also 
important to ensure that the items that were not amenable to the generation of health states were 
removed.  This process was carried out by an expert panel who assessed each of the five factors as 
well as the items that were not included in the five factor model.  Changes relating to four factors 
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are described below.  Table 3 displays the dimensions that were used to develop the classification 
system: 
Worry about seizures: 
Following clinical input regarding the importance of worry relating to past and potential future 
seizures on epilepsy patients HRQL, it was decided to include an extra dimension investigating worry 
and anxiety about seizures. This dimension included two items investigating worry about past and 
future seizures.  
Memory and cognition: 
The memory and cognition factor investigates two different facets of HRQL.  As no item covers both 
concepts, selecting one item for this factor would mean removing an area of HRQL from the 
classification system that may be important in a neuropsychological condition such as epilepsy.  
Following this it was decided to split the factor into memory and cognition sub-dimensions and 
perform the Rasch analysis on each. Most of the items in this factor were taken from the ABNAS.  
Therefore the items included in the sub-dimensions was informed by the original factor analysis of 
this measure (Aldenkamp and Baker, 1997) which found a six dimension structure, with factors 
defined as fatigue, slowing, memory, concentration, motor coordination and language.  Items from 
the concentration, slowing and language factors were included in the cognition sub-dimension.  
Items from the memory factor were included in the memory sub-dimension.  Items from the fatigue 
and motor coordination factors and non relevant somatic items from the AEP related to 
unsteadiness and dizziness were removed from the analysis at this stage.   
Mental health: 
The mental health factor includes items relating to concepts that could broadly be defined as 
depression and anxiety. Therefore it was decided to split the items into depression and anxiety sub-
dimensions.  The majority of the items in this factor are taken from the HADS, and therefore the sub-
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dimension split was informed by the original development of this instrument which includes 
depression and anxiety subscales (Zigmond and Snaith, 1983).  Research suggests that anxiety in 
epilepsy is associated with increased seizure activity (Jacoby et al., 1996) and poor seizure control 
(Mensah et al., 2007).  Therefore as the worry about seizures dimension focuses more on epilepsy 
specific anxiety rather than the more general focus of the anxiety sub-dimension, it was decided to 
use the worry about seizures dimension to investigate anxiety.  The anxiety sub-dimension was 
excluded from further consideration.   
Impact of epilepsy 
The wording of the impact factor items means that it is not possible to generate health state levels.  
This is because the items are transition questions that ask how epilepsy has affected ‘for better or 
worse’ an area of the patient’s life (for example their relationship with their friends).  Therefore this 
dimension was not included in the health state classification system.  
 
Rasch analysis and item selection by dimension 
The item selection process for each of the six NEWQOL factors is described below. Tables 4 and 5 
display in detail psychometric and Rasch analysis results for each of the items included in each 
dimension.   
Cognition: 
Stage 2: Item elimination 
The cognition sub-dimension includes 10 items from the ABNAS scale.  Across both the initial and 
validation analyses, items b (‘My mind does not work as fast as it should’) and h (‘My thinking has 
slowed down’) display DIF by age and item j (‘I have difficulty concentrating on the things that I am 
doing’) does not fit the Rasch model.  These items were therefore no longer considered for selection 
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to the health state classification system.  Three further items were also excluded from selection due 
to both DIF by age and misfit to the Rasch model on either the initial or validation analysis.  These 
are item d (‘I have difficulties in following a book or film’), item f (‘I have problems finding the 
correct word’) and item v (‘I sometimes stutter or am unable to find the correct words’).   
Stage 3: Item selection 
Across the analyses, four items remained for selection.  Of these, item l (‘I have problems 
understanding what I read’) displayed low spread at logit 0 so was not considered further.   Items p 
(‘I can’t concentrate for more than a short period of time’), u (‘I get distracted easily’) and w (‘I feel I 
react too slowly to things that are said to me’) all display similar severity coverage and coverage at 
logit 0 across both analyses.  Of these, p was selected as the item assesses a cognition related issue 
that is more general, and therefore more prevalent, than the concepts covered by the other 
remaining items.    
Memory: 
Stage 2: Item elimination 
The memory component of the overall memory and cognition factor includes 5 items.  Across both 
the initial and validation analysis, ABNAS item c (‘I have difficulties remembering the names of 
people’) displays uniform DIF by age and ABNAS o (‘I forget things people have said to me’) does not 
fit the model.  Both items were removed from consideration for the health state classification.  On 
the initial analysis, ABNAS t (‘I get confused and forget what I was doing’) displayed DIF by age and 
on the validation analysis ABNAS i (‘I forget all kinds of things, for example an appointment’) did not 
fit the Rasch model.   
Stage 3: Item selection 
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The only remaining item from across both analyses was AEP 18 (‘memory problems’) and this item 
was selected for the health state classification system. 
Depression: 
Stage 2: Item elimination 
Six items are included in the depression component of the mental health factor.  Across both the 
initial and validation analysis, HADS items 2 (‘I can still enjoy the things I used to enjoy’) and 14 (‘I 
can enjoy a good book or radio or TV program’) were disordered and HADS 12 (‘I look forward with 
enjoyment to things’) displayed DIF by age.  HADS item 6(‘I feel cheerful’) displayed DIF by age on 
the validation analysis.  These four items were not considered for the health state classification 
system. 
Stage 3: Item selection: 
Two items remain for selection to the classification system.  These are AEP 17 (‘Depression’) and 
HADS 4 (‘I can laugh and see the funny side of things’).  Although HADS item 4 displays better range 
and spread than AEP item 17 it was decided to use AEP item 17 as the item assesses the overall 
factor concept directly. Control: 
Stage 2: Item elimination 
The control dimension includes 5 items, and the response categories for all of the items are ordered 
on the logit scale.  Control items b (‘I sometimes feel that I am pushed around in my life’) and g 
(‘There is little I can do to change many of the important things in my life’) display DIF by age on 
both of the analyses, and control item e (‘I often feel helpless in dealing with the problems of life’) 
displays DIF by gender on the initial analysis.   
Stage 3: Item selection 
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Two items (control a: ‘There is really no way I can solve some of the problems I have’ and control c: ‘I 
have little control over things that happen to me’) remain for selection.  Of these, control c covers 
more of the severe end of the severity spectrum and displays larger spread at logit 0 so was 
therefore selected for the classification system 
Stigma: 
Stage 2: Item elimination 
The stigma domain contains 3 items. Stigma item a (‘I feel some people are uncomfortable with me’) 
has been eliminated due to poor fit to the Rasch model and this is consistent across both halves of 
the analysis.   
Stage 3: Item selection 
On both the initial and validation analyses two stigma items remain for selection (Stigma b: ‘I feel 
some people treat me like an inferior person’ and stigma c: ‘I feel some people would prefer to avoid 
me’). Both of the remaining items have a high ceiling effect, though item b displays slightly better 
severity coverage and overall item fit.  Clinical input also suggests that item b may be the more able 
to discriminate between severity levels and therefore this item was selected for the health state 
classification. 
Worry about seizures: 
Stage 2: Item elimination: 
Of the two items included in the worry factor, both are ordered on both the initial and validation 
analyses.  Neither item displayed DIF and both displayed goodness of fit to the model so neither was 
eliminated at this stage. 
Stage 3: Item selection: 
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Both of the items cover the full severity range in terms of item range and spread. As both items are 
valid for the health state classification it was decided to select the item assessing worry about future 
seizures as this is the most relevant for those with newly diagnosed epilepsy.  
 
Stage 4: Item level ordering 
The item level ordering and response distribution across the levels was investigated for each of the 
selected items. Each of the six items has 4 response levels and this was maintained for the 
classification system as Rasch analysis demonstrated that of all the categories were ordered on the 
logit scale, and would therefore be amenable to health state valuation. 
 
Final health state classification: 
The final six dimension health state classification is displayed in figure 1, with the final health states 
developed in accordance with the response levels assigned to the original item.  The classification 
system generates a possible 4096 (46) health states, a selection of which will be valued by a general 
population and patient sample. 
 
Discussion: 
This technical report describes the development of a health state classification system for epilepsy 
from NEWQOL, a condition specific measure of HRQL.  This was carried outusing a combination of 
classical psychometric techniques and Rasch analysis.  We have completed the first stage of the 
process of developing an epilepsy specific preference based measure by identifying a tool that can 
now be valued using a standard preference elicitation technique.  This work is the first attempt to 
derive a condition specific classification system for epilepsy for the purposes of cost utility analysis 
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using QALYs.  It is also the first attempt to derive a classification system from a battery that includes 
a variety of standardised measures that were developed for epilepsy (for example ABNAS and AEP) 
and also a widely used measure (HADS) that was not specifically developed for use in epilepsy but is 
an accepted measure of depression and anxiety across a range of conditions (Bjellend et al., 2002).  
This is also the first reported study to develop a classification system for a neuropsychological 
condition. 
This study has built on previous work by members of the research group using the results of Rasch 
and psychometric analysis to develop condition specific classification systems for over active bladder 
(Young et al, 2009), asthma (Young et al.,2010) and dementia (Mulhern et al., 2010).  Again it has 
been demonstrated that these analyses can help guide the selection of items for a reduced health 
state classification system.  The analysis quantifies the performance of the items and clinical input 
during the selection process maximises face validity and enables the best item to be selected if the 
Rasch statistics of a number of items are similar. 
 
The use of generic measures such as the EQ-5D and SF-6D in epilepsy has been criticised as it has 
been found that they do not fully reflect the impact of the condition, and may not cover all of the 
relevant domains (Selai et al, 2000; Stavem et al, 2001).  Therefore the cost utility estimations gained 
using generic measures may not be fully accurate.  The final instrument that will be available 
following valuation may address some of these concerns.  Further work should use both generic and 
condition specific PBMs in intervention trials both to increase the strength of the conclusions 
relating to the cost utility analysis and to subsequently assess the performance of the measures. 
 
The classification system that has been developed may possibly be criticised for not covering all of 
the relevant HRQL domains related to epilepsy.  For example social and activity restrictions due to 
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epilepsy is not covered.  This  is a consequence of the social activity limitation items included in the 
NEWQOL which cannot be used in a health state classification system because of the wording of the 
item and response options.  Further work may investigate the possibility of using bolt-on dimensions 
to cover omissions and this possibility is been investigated in asthma (Brazier et al, 2010).  A possible 
bolt on for this instrument may be the usual activities domain of the EQ-5D.  It may also be possible 
to add a dimension by applying the techniques described here to epilepsy specific items from other 
instruments.  This may particularly fit here as the items included in the classification system are 
already drawn from a variety of measures, and as such may be amenable to bolt-on dimensions. 
 
We have completed the first stage of the development of a condition specific preference based 
measure, which is the generation of a health state classification system from a parent instrument 
using a combination of analysis techniques. The next stage of the process involves the valuation of a 
set of the health states generated using the preference elicitation technique Time Trade-Off (TTO) 
(for example see Yang et al, 2008).  Health states will be valued by both the general population and 
by epilepsy patients, and the general population preference weights will be used in economic 
evaluations to complement those gained by using generic measures such as the EQ-5D.  This will be 
initially tested by application to the SANAD dataset (Marson et al., 2005, 2007), to calculate the 
incremental costs per QALY and compare with the EQ-5D-based estimates. The new instrument may 
also be used when generic utility scores are not available and will help to address some of the 
concerns around using generic PBMs in epilepsy.   The measure will provide a useful tool for those 
concerned with the allocation of resources to epilepsy interventions.  
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Table 1: Items included in NEWQOL subset (adapted from Abetz et al., 2000) 
Scale name Subscales and items Scale definition 
Worry about seizures scale 2 items Measures worry about past and possible future seizures using a 
4-point scale 
Liverpool Adverse Events 
profile 
19 items Measures a range of adverse events using a 4-point frequency 
scale 
Hospital Anxiety and 
Depression Scale 
14 items, anxiety (7) and 
depression (7) subscales 
Identifies clinical cases of anxiety and depression using 5-point 
scales 
Social limitations  1 item Assesses the extent of perceived limitation of social activities on 
a 4-point scale 
Mastery/locus of control 
scale 
7 items Measures degree of internal vs. external locus of control using a 
4-point scale 
Stigma of epilepsy scale 3 items Measures perceived level of stigma associated with epilepsy 
using a 4-point scale 
Impact of seizures scale 12 items Measures the perceived impact of seizures on a range of life 
areas using a 5-point scale  
AB Neuropsychological 
Assessment Schedule 
24 items, fatigue (8), 
memory (5), concentration 
(6), motor (3) and reading (2) 
subscales 
Measures 5 aspects of cognitive function using a 4-point scale 
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Table 2: NEWQOL 5 factor structure 
Factor Item Original 
measure 
Loading 
1. Memory and cognition My thinking has slowed down ABNAS (h) 0.806 
 I forget all kinds of things, for example an 
appointment or where I put an object 
ABNAS (i) 0.780 
 I have difficulty concentrating on the things that I am 
doing. 
ABNAS (j) 0.780 
 I get confused and forget what I was doing ABNAS (t) 0.771 
 I forget things people have said to me ABNAS (o) 0.763 
 My mind does not work as fast as it should ABNAS (b) 0.760 
 I can’t concentrate for more than a short period of 
time 
ABNAS (p) 0.747 
 I feel I react too slowly to things that are said to me ABNAS (w) 0.745 
 I have problems finding the correct word ABNAS (f) 0.744 
 I sometimes stutter or am unable to find the correct 
words 
ABNAS (v) 0.708 
 I get distracted easily ABNAS (u) 0.707 
 I have difficulties remembering the names of people ABNAS (c) 0.674 
 I feel clumsy ABNAS (e) 0.665 
 I am less capable of getting started on doing things ABNAS (g) 0.658 
 I have difficulties in following a book or film ABNAS (d) 0.653 
 I cannot keep an activity going for long ABNAS (x) 0.651 
 Memory problems AEP (18) 0.636 
 I have problems understanding what I read ABNAS (l) 0.614 
 I constantly bump against tables, doorposts, etc ABNAS (q) 0.547 
 Unsteadiness AEP (1) 0.433 
 Dizziness AEP (15) 0.421 
 I cannot use a pen or pencil accurately ABNAS (k) 0.421 
    
2. Mental health I feel cheerful HADS (6) 0.679 
 I look forward with enjoyment to things HADS (12) 0.623 
 I can sit at ease and feel relaxed HADS (7) 0.622 
 I can laugh and see the funny side of things HADS (4) 0.618 
 I still enjoy the things I used to enjoy HADS (2) 0.599 
 I feel tense or ‘wound up’ HADS (1) 0.560 
 Depression AEP (17) 0.559 
 I can enjoy a good book or radio or TV program HADS (14) 0.515 
 Worrying thoughts go through my mind HADS (5) 0.503 
 Feelings of aggression AEP (4) 0.436 
    
3. Impact Attacks effect the kind of paid work you can do Impact (e) 0.744 
 Attacks effect whether or not you are able to work in 
paid employment 
Impact (d) 0.708 
 Attacks effect your standard of living Impact (j) 0.645 
 Attacks effect your plans and ambitions for the future Impact (i) 0.603 
 Attacks effect your social life and social activities Impact (c) 0.526 
 Social activity restriction level Social (1) -0.517 
 Attacks effect your the level of your independence Impact (l) 0.494 
 Attacks effect your health overall Impact (f) 0.485 
 Attacks effect the way you feel about yourself Impact (h) 0.469 
    
4. Control I have little control over things that happen to me Control (c) -0.654 
 I often feel helpless in dealing with the problems of 
life 
Control (e) -0.571 
 I sometimes feel that I am pushed around in my life Control (b) -0.557 
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 There is really no way I can solve some of the 
problems I have 
Control (a) -0.553 
 There is little I can do to change many of the 
important things in my life 
Control (g) -0.546 
    
5. Stigmatism I feel some people would prefer to avoid me Stigma (c) 0.798 
 I feel some people treat me like an inferior person Stigma (b) 0.710 
 I feel some people are uncomfortable with me Stigma (a) 0.662 
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Table 3:  
Dimension Item 
Cognition My mind does not work as fast as it should 
 I have difficulties in following a book or film 
 I have problems finding the correct word 
 My thinking has slowed down 
 I have difficulty concentrating on the things that I am doing. 
 I have problems understanding what I read 
 I can’t concentrate for more than a short period of time 
 I get distracted easily 
 I sometimes stutter or am unable to find the correct words 
 I feel I react too slowly to things that are said to me 
  
Memory Memory problems 
 I have difficulties remembering the names of people 
 I forget all kinds of things, for example an appointment or where I put an object 
 I forget things people have said to me 
 I get confused and forget what I was doing 
  
Depression Depression 
 I still enjoy the things I used to enjoy 
 I can laugh and see the funny side of things 
 I feel cheerful 
 I look forward with enjoyment to things 
 I can enjoy a good book or radio or TV program 
  
Control There is really no way I can solve some of the problems I have 
 I sometimes feel that I am pushed around in my life 
 I have little control over things that happen to me 
 I often feel helpless in dealing with the problems of life                                                    
 There is little I can do to change many of the important things in my life 
Stigmatism I feel some people are uncomfortable with me 
 I feel some people treat me like an inferior person 
 I feel some people would prefer to avoid me 
Worry How worried are you about the attacks you have had? 
 How worried are you that you might have another attack? 
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Table 4: Rasch analysis for data half 1 
Half 1 analysis  Classical   Rasch       
Factor                                 Item Factor 
loading 
% 
floor 
% 
ceiling 
Missing SRM1                Disordered Item range Fit 
resid 
Chi p 
value 
Spread at 
logit 0 
DIF Poor 
fit  
Cognition             
 My mind does not work as fast as it should 0.76 12 34 1.9 -0.01      Age  
 I have difficulties in following a book or film 0.65 7 60 2.2 -0.06  -0.39 to 1.55 2.14 0.12 0.18 to 0.60   
 I have problems finding the correct word 0.74 10 40 2.0 -0.17       Yes 
 My thinking has slowed down 0.81 11 38 2.0 -0.04      Age  
 I have difficulty concentrating on the things that I 
am doing. 
0.78 10 41 2.3 -0.01       Yes 
 I have problems understanding what I read 0.61 4 68 2.5 -0.09  0.13 to 2.51 1.04 0.69 0.07 to 0.47   
 I can’t concentrate for more than a short period 
of time 
0.74 8 47 1.7 -0.09  -1.42 to 1.78 -2.33 0.02 0.14 to 0.80   
 I get distracted easily 0.71 9 43 2.0 -0.06  -1.65 to 1.61 -0.43 0.01 0.17 to 0.84   
 I sometimes stutter or am unable to find the 
correct words 
0.71 9 46 1.6 -0.04       Yes 
 I feel I react too slowly to things that are said to 
me 
0.75 7 52 1.6 0.02  -1.05 to 2.17 -1.64 0.11 0.10 to 0.74   
Memory             
 Memory problems 0.64 22 23 1.8 -0.08  -2.37 to 0.58 1.22 0.58 0.36 to 0.91   
 I have difficulties remembering the names of 
people 
0.67 11 44 2.0 -0.24      Age  
 I forget all kinds of things, for example an 
appointment 
0.78 16 36 2.2 -0.10  -1.78 to 0.80 -0.95 0.01 0.31 to 0.86   
 I forget things that people have said to me 0.76 11 33 1.6 0.01       Yes 
 I get confused and forget what I was doing 0.77 10 49 1.8 0.02      Age  
Depression             
 Depression 0.559 13 36 2.2 0.14  -2.04 to 0.64 1.63 0.43 0.35 to 0.88   
 I still enjoy the things I used to enjoy 0.599 9 42 0.9 0.03 Yes (Not quite so 
much/only a little) 
    Age  
 I can laugh and see the funny side of things 0.618 2 61 0.8 0.02  -0.71 to 2.63 0.41 0.05 0.07 to 0.67   
 I feel cheerful 0.679 3 48 0.7 -0.07  -1.53 to 2.20 -0.38 0.08 0.10 to 0.82   
 I look forward with enjoyment to things 0.623 4 51 1.1 0.03      Age  
 I can enjoy a good book or radio or TV program 0.515 5 60 0.7 0.00 Yes (sometimes/not 
often) 
     Yes 
Control             
 There is really no way I can solve some of the 
problems I have 
-0.553 16 17 2.5 -0.01  -1.96 to 0.74 1.96 0.46 0.32 to 0.88   
 I sometimes feel that I am pushed around in my -0.557 7 25 2.0 -0.02      Age  
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Half 1 analysis  Classical   Rasch       
Factor                                 Item Factor 
loading 
% 
floor 
% 
ceiling 
Missing SRM1                Disordered Item range Fit 
resid 
Chi p 
value 
Spread at 
logit 0 
DIF Poor 
fit  
life 
 I have little control over things that happen to 
me 
-0.654 10 20 2.6 -0.14  -1.86 to 1.57 -1.57 0.01 0.17 to 0.87   
 I often feel helpless in dealing with the problems 
of life 
-0.571 10 19 2.0 -0.07      Gender  
 There is little I can do to change many of the 
important things  
-0.546 10 19 2.2 -0.08      Age  
Stigmatism             
 I feel some people are uncomfortable with me 0.662 9 52 1.7 0.10       Yes 
 I feel some people treat me like an inferior 
person 
0.710 5 68 2.4 0.02  -1.54 to 1.38 0.93 0.44 0.20 to 0.82   
 I feel some people would prefer to avoid me 0.798 5 69 2.6 -0.03  -1.40 to 1.39 0.84 0.28 0.20 to 0.80   
Worry             
 Worried about attacks you have had  33 7 0.6 -0.85  -3.36 to 3.64 -0.12 0.55 0.03 to 0.97   
 Worried might have another attack  38 6 0.4 -0.70  -3.78 to 2.96 -0.38 0.11 0.05 to 0.98   
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Table 5: Rasch analysis for data half 2  
Half 2 analysis1 Classical   Rasch      
Factor                              Item Factor 
loading 
% 
floor 
% 
ceiling 
Missing SRM1 Disordered Item range Fit 
resid 
Chi p 
value 
Spread at 
logit  
DIF Poor fit  
Cognition             
 My mind does not work as fast as it should 0.76 12 34 1.9 -0.01      Age  
 I have difficulties in following a book or film 0.65 7 60 2.2 -0.06      Age  
 I have problems finding the correct word 0.74 10 40 2.0 -0.17      Age  
 My thinking has slowed down 0.81 11 38 2.0 -0.04      Age  
 I have difficulty concentrating on the things 
that I am doing. 
0.78 10 41 2.3 -0.01       Yes 
 I have problems understanding what I read 0.61 4 68 2.5 -0.09  0.24 to 1.85 0.80 0.32 0.14 to 0.44   
 I can’t concentrate for more than a short 
period of time 
0.74 8 47 1.7 -0.09  -1.49 to 1.56 -2.46 0.03 0.17 to 0.82   
 I get distracted easily 0.71 9 43 2.0 -0.06  -1.75 to 1.39 0.01 0.47 0.20 to 0.85   
 I sometimes stutter or am unable to find 
the correct words 
0.71 9 46 1.6 -0.04  -1.28 to 1.06 2.25 0.04 0.26 to 0.78   
 I feel I react too slowly to things that are 
said to me 
0.75 7 52 1.6 0.02  -1.25 to 1.56 -0.97 0.19 0.17 to 0.78   
Memory             
 Memory problems 0.64 22 23 1.8 -0.08  -2.36 to 0.63 0.10 0.09 0.35 to 0.91   
 I have difficulties remembering the names 
of people 
0.67 11 44 2.0 -0.24      Age  
 I forget all kinds of things, for example an 
appointment 
0.78 16 36 2.2 -0.10       Yes 
 I forget things that people have said to me 0.76 11 33 1.6 0.01       Yes 
 I get confused and forget what I was doing 0.77 10 49 1.8 0.02  -0.64 to 1.73 0.55 0.07 0.15 to 0.65   
Depression             
 Depression 0.559 13 36 2.2 0.14  -2.20 to 0.44 2.34 0.95 0.39 to 0.90   
 I still enjoy the things I used to enjoy 0.599 9 42 0.9 0.03 Yes (not quite so 
much/only a little) 
    Age  
 I can laugh and see the funny side of things 0.618 2 61 0.8 0.02  -0.93 to 2.87 -0.44 0.04 0.05 to 0.72   
 I feel cheerful 0.679 3 48 0.7 -0.07      Age   
 I look forward with enjoyment to things 0.623 4 51 1.1 0.03      Age  
 I can enjoy a good book or radio or TV 
program 
0.515 5 60 0.7 0.00 Yes (sometimes/not 
often) 
     Yes 
Control             
 There is really no way I can solve some of 
the problems I have 
-0.553 16 17 2.5 -0.01  -2.27 to 0.76 0.01 0.50 0.32 to 0.91 
 
  
 I sometimes feel that I am pushed around -0.557 7 25 2.0 -0.02      Age  
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Half 2 analysis1 Classical   Rasch      
Factor                              Item Factor 
loading 
% 
floor 
% 
ceiling 
Missing SRM1 Disordered Item range Fit 
resid 
Chi p 
value 
Spread at 
logit  
DIF Poor fit  
in my life 
 I have little control over things that happen 
to me 
-0.654 10 20 2.6 -0.14  -2.11 to 1.35 -0.50 0.10 0.21 to 0.89   
 I often feel helpless in dealing with the 
problems of life 
-0.571 10 19 2.0 -0.07  -2.05 to 1.49 0.01 0.22 0.18 to 0.89   
 There is little I can do to change many of 
the important things 
-0.546 10 19 2.2 -0.08      Age  
Stigmatism             
 I feel some people are uncomfortable with 
me 
0.662 9 52 1.7 0.10       Yes 
 I feel some people treat me like an inferior 
person 
0.710 5 68 2.4 0.02  -1.23 to 1.24 0.93 0.26 0.22 to 0.77   
 I feel some people would prefer to avoid 
me 
0.798 5 69 2.6 -0.03  -1.25 to 0.69 0.88 0.29 0.34 to 0.78   
Worry             
 Worried about the attacks you have had  33 7 0.6 -0.85  -3.07 to 3.38 0.07 0.51 0.03 to 0.96   
 Worried have another attack  38 6 0.4 -0.70  -3.34 to 2.88 -0.01 0.28 0.05 to 0.97   
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Fig 1: Flow diagram of the process used to derive a condition specific health state classification 
system from a non-preference based measure 
 
  Stage I 
Establish dimensions using factor analysis alongside input from 
epilepsy clinicians and the developers of the NEWQOL instrument 
Stage II 
Rasch analysis used to eliminate items per dimension 
Stage III 
Rasch and other psychometric analyses used to select one item 
per dimension 
 
Stage IV 
Rasch analysis used to explore item level reducing per domain 
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Figure 2: Final health state classification system 
Worry about attacks 
You are not worried at all that you might have another epileptic attack 
You are a little worried that you might have another epileptic attack 
You are fairly worried that you might have another epileptic attack 
You are very worried that you might have another epileptic attack 
 
Depression 
You never have problems with depression 
You rarely have problems with depression 
You sometimes have problems with depression 
You always or often have problems with depression 
 
Memory 
You never have problems with your memory 
You rarely have problems with your memory 
You sometimes have problems with your memory 
You always or often have problems with your memory 
 
Concentration 
You have no problem concentrating for more than a short period of time 
You have mild problems concentrating for more than a short period of time 
You have moderate problems concentrating for more than a short period of time 
You have serious problems concentrating for more than a short period of time 
 
Control 
You feel that you have complete control over things that happen to you 
You feel that you have some control over things that happen to you 
You feel that you have little control over things that happen to you 
You feel that you have no control over things that happen to you 
 
Stigma 
You do not feel that people treat you like an inferior person 
You feel that some people maybe treat you like an inferior person 
You feel that some people probably treat you like an inferior person 
You feel that some people definitely treat you like an inferior person 
 
